INH-A21: a donor-selected Staphylococcal human immune globulin for the prevention of late-onset neonatal Staphylococcal infection.

abstract：INTRODUCTION:The introduction and exploration of novel agents has significantly improved patient outcome in the treatment of multiple myeloma (MM). One such compound, bortezomib, was the first proteasome inhibitor (PI) to be approved as a MM therapeutic. The efficacy and safety data provided by bortezomib usage has pro...

journal_title：Expert opinion on investigational drugs

authors： Bringhen S,Gay F,Donato F,Troia R,Mina R,Palumbo A

更新日期：2014-09-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Contrasting with the broad activation of the PI3K/AKT/mammalian target of rapamycin (mTOR) survival pathway in most cancer, activity of rapalogues appears to be restricted to a few tumor types. AREAS COVERED IN THIS REVIEW:The analysis of molecular activity of the PI3K/AKT/mTOR pathway and resi...

journal_title：Expert opinion on investigational drugs

authors： Albert S,Serova M,Dreyer C,Sablin MP,Faivre S,Raymond E

更新日期：2010-08-01 00:00:00

abstract：INTRODUCTION:Since the discovery of the activating V617F mutation in Janus kinase 2 (JAK2), a number of pharmacologic inhibitors of JAK2 have entered clinical trials for patients with myelofibrosis. However, ruxolitinib, approved in 2011, remains the only one currently available for treatment of myelofibrosis, with man...

journal_title：Expert opinion on investigational drugs

authors： Bose P,Abou Zahr A,Verstovsek S

更新日期：2017-06-01 00:00:00

abstract：:The deposition of a platelet rich thrombus on an atherosclerotic plaque is a critical step in the development of unstable coronary syndromes. Currently available therapeutic agents such as aspirin and ticlopidine are relatively weak inhibitors of platelet aggregation. Recently, antagonists to platelet glycoprotein IIb...

journal_title：Expert opinion on investigational drugs

authors： Kumar A,Herrmann HC

更新日期：1997-09-01 00:00:00

abstract：INTRODUCTION:There has been a striking increase in the emergence of multidrug-resistant pathogens in recent times. Delafloxacin is a novel, broad-spectrum fluoroquinolone with antimicrobial activity against resistant Gram-positive, Gram-negative and anaerobic organisms. It has the potential to treat a variety of infect...

journal_title：Expert opinion on investigational drugs

authors： Bassetti M,Della Siega P,Pecori D,Scarparo C,Righi E

更新日期：2015-03-01 00:00:00

abstract：:TNP-470, an analogue of fumagillin, has been shown to inhibit angiogenesis in vitro and in vivo. In 1992, TNP-470 entered clinical development for cancer as an anti-angiogenic agent. It is currently in Phase I/II trials in Kaposi's sarcoma, renal cell carcinoma, brain cancer, breast cancer, cervical cancer and prostat...

journal_title：Expert opinion on investigational drugs

authors： Kruger EA,Figg WD

更新日期：2000-06-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Aspirin, an irreversible inhibitor of thromboxane A(2) production, in combination with clopidogrel, an inhibitor of PY(12) ADP platelet receptors, represents the current standard-of-care of antiplatelet therapy for patients with acute coronary syndrome and those undergoing percutaneous coronary ...

journal_title：Expert opinion on investigational drugs

authors： Tomasello SD,Angiolillo DJ,Goto S

更新日期：2010-12-01 00:00:00

abstract：:Preclinical studies suggest that the brain corticotropin-releasing factor (CRF) systems mediate anxiety-like behavioural and somatic responses through actions at the CRF1 receptor. CRF1 antagonists block the anxiogenic-like effects of CRF and stress in animal models. Cerebrospinal fluid levels of CRF are elevated in s...

journal_title：Expert opinion on investigational drugs

authors： Zorrilla EP,Koob GF

更新日期：2004-07-01 00:00:00

abstract：:The fact that PPAR-gamma is expressed dramatically higher in fat, regulating gene transcription in response to small lipophilic ligands, supports an essential role of increased lipophilicity for those ligands. On the other hand, the skepticism concerning high lipophilicity as a characteristic associated with undesirab...

journal_title：Expert opinion on investigational drugs

authors： Giaginis C,Theocharis S,Tsantili-Kakoulidou A

更新日期：2007-04-01 00:00:00

abstract：:Helicobacter pylori infection causes peptic ulcer disease and must be regarded as a serious infectious disease. Over the past two decades treatment of the infection has been a controversial issue. Treatment is purely empirical and based on combinations of two, three or four existing drugs. Antimicrobial resistance is ...

journal_title：Expert opinion on investigational drugs

authors： de Boer WA

更新日期：2001-08-01 00:00:00

abstract：:After thousands of years of interest the last few decades have seen a huge increase in our knowledge of the cannabinoids and their mode of action. Their potential as medical therapeutics has long been known. However, very real concerns over their safety and efficacy have lead to caution and suspicion when applying the...

journal_title：Expert opinion on investigational drugs

authors： Grundy RI

更新日期：2002-10-01 00:00:00

abstract：INTRODUCTION:Axial spondyloarthritis (AxS pA) is a chronic inflammatory disease for which, until recently, there were no valid therapeutic alternatives to TNF-α blocking agents. This unmet clinical need led to explore several therapeutic targets, from proinflammatory cytokines to intracellular signaling systems. The re...

journal_title：Expert opinion on investigational drugs

authors： Clavel G,Boissier MC,Sigaux J,Semerano L

更新日期：2017-07-01 00:00:00

abstract：:Phytoestrogens, such as the soya isoflavones genistein and daidzein, are currently being extensively investigated through both molecular, preclinical and clinical studies to determine their potential health benefits. Phytoestrogens may protect against chronic diseases such as hormone-dependent cancer (e.g., breast and...

journal_title：Expert opinion on investigational drugs

authors： Wiseman H

更新日期：2000-08-01 00:00:00

abstract：:Parkinson's disease (PD) is a neurodegenerative disorder associated with the loss of dopaminergic neurons in the substantia nigra. The decline of dopamine leads to motor dysfunctions manifested as tremor, rigidity and bradykinesia. The pharmacological treatment of choice for the past 30 years has primarily been the do...

journal_title：Expert opinion on investigational drugs

authors： Tuite P,Riss J

更新日期：2003-08-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Several studies have demonstrated the high prevalence of hypertension and the crucial role of the association between endothelial function and hypertension. Thus, in depth investigation of the pathophysiological mechanisms linking endothelial dysfunction and hypertension, as well as evaluation o...

journal_title：Expert opinion on investigational drugs

authors： Tousoulis D,Papageorgiou N,Androulakis E,Paroutoglou K,Stefanadis C

更新日期：2010-11-01 00:00:00

abstract：INTRODUCTION:Inhibitors against the PD-1/PD-L1 pathway are revolutionizing the treatment and management of malignancies. AREAS COVERED:We summarize our current understanding of the function of PD-1, its role in immune evasion, the clinical data available that support the use of PD-1 antagonist in Hodgkin and non-Hodgk...

journal_title：Expert opinion on investigational drugs

authors： Chang A,Schlafer D,Flowers CR,Allen PB

更新日期：2018-01-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Migraine is an episodic, substantially inherited brain disorder affecting 15% of adults in Western Europe and North America, and is one of the commonest reasons for patients to see their physicians. While the World Health Organization considers that severe migraine can be as disabling as quadrip...

journal_title：Expert opinion on investigational drugs

authors： Marin JC,Goadsby PJ

更新日期：2010-04-01 00:00:00

abstract：:Oxcarbazepine (OXC) was introduced in 1990 and is now registered in 54 countries worldwide as monotherapy, as add-on treatment for partial seizures, with or without secondarily generalised seizures, and primary generalised tonic-clonic seizures. OXC and its active metabolite, monohydroxy derivative (MHD), block voltag...

journal_title：Expert opinion on investigational drugs

authors： Schachter SC

更新日期：1999-07-01 00:00:00

abstract：INTRODUCTION:The introduction of therapy with tumor necrosis factor antagonists (aTNF) was a cornerstone of treatment modalities in patients with ankylosing spondylitis (AS). After > 10 years of using aTNF, the introduction of aTNF therapy was a major step forward in the medical management of patients with spondyloarth...

journal_title：Expert opinion on investigational drugs

authors： Braun J,Baraliakos X,Heldmann F,Kiltz U

更新日期：2014-05-01 00:00:00

abstract：:The management of acute myocardial infarction (AMI) has changed dramatically over the last two decades, with the addition of fibrinolytic agents and primary coronary intervention (PCI). The more recent development of the glycoprotein (GP) IIb/IIIa antagonists, a new class of potent antiplatelet drugs, has the potentia...

journal_title：Expert opinion on investigational drugs

authors： Ferguson JJ,Vaisman D

更新日期：2001-11-01 00:00:00

abstract：INTRODUCTION:The Philadelphia chromosome negative myeloproliferative neoplasms (MPN) mainly comprise polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF, primary or post-PV/ET). Therapy in PV and ET focuses on minimizing thrombosis and bleeding risk, while in MF, prolongation of survival is an ...

journal_title：Expert opinion on investigational drugs

authors： Bose P,Verstovsek S

更新日期：2016-12-01 00:00:00

abstract：INTRODUCTION:Inhaled corticosteroids are the only drugs that effectively suppress the airway inflammation, but they can induce considerable systemic and adverse effects when they are administered chronically at high doses. Consequently, the pharmaceutical industry is still searching for newer entities with an improved ...

journal_title：Expert opinion on investigational drugs

authors： Cazzola M,Coppola A,Rogliani P,Matera MG

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Minimal change disease (MCD) and Focal and segmental glomerulosclerosis (FSGS) are two of the major causes of nephrotic syndrome (NS) in children and adults. According to KDIGO (Kidney Disease: Improving Global Outcomes) guidelines, the treatment of adult primary MCD and FSGS should be based on immunosuppr...

journal_title：Expert opinion on investigational drugs

authors： Siligato R,Cernaro V,Nardi C,De Gregorio F,Gembillo G,Costantino G,Conti G,Buemi M,Santoro D

更新日期：2018-11-01 00:00:00

abstract：:Endothelin (ET) is a pivotal physiological regulator of blood pressure through its effects on blood vessels, heart, lung and kidneys, and the ET system can be overactive in disorders such as pulmonary hypertension, heart failure and renal disease. Such observations stimulated interest among scientists and pharmaceutic...

journal_title：Expert opinion on investigational drugs

authors： Benigni A,Perico N,Remuzzi G

更新日期：2004-11-01 00:00:00

abstract：:Venous and arterial thromboembolism are a major cause for morbidity and mortality. The list of established drugs for the prevention of thrombus formation and embolisation includes heparins, hirudin and derivatives, aspirin, ADP and glycoprotein IIb/IIIa receptor antagonists, as well as vitamin K antagonists. Several l...

journal_title：Expert opinion on investigational drugs

authors： Ruef J,Katus HA

更新日期：2003-05-01 00:00:00

abstract：:Argatroban, a synthetic peptidomimetic antithrombin agent, is the first clinical anticoagulant solely to target thrombin. For some time, this drug has been used in Japan for the management of thromboembolic disorders. Recently, it has been approved in Japan for use in thrombotic and ischaemic stroke. Despite a large n...

journal_title：Expert opinion on investigational drugs

authors： Jeske W,Walenga JM,Lewis BE,Fareed J

更新日期：1999-05-01 00:00:00

abstract：:A recent study has demonstrated for the first time that botulinum neurotoxin (BoNT) briefly opens tumour vessels, allowing more effective destruction of cancer cells by radiotherapy and chemotherapy. This review discusses the implications of BoNTs in cancer treatment. After briefly reviewing the different BoNT serotyp...

journal_title：Expert opinion on investigational drugs

authors： Ansiaux R,Gallez B

更新日期：2007-02-01 00:00:00

abstract：:The interaction between the urokinase receptor (uPAR) and its ligand urokinase (uPA) mediates phenomena such as tissue remodelling, chemotaxis, tumour invasion, dissemination, proliferation, and angiogenesis. The broad-spectrum of biological processes that the uPA/uPAR interaction plays a role in has led researchers t...

journal_title：Expert opinion on investigational drugs

authors： Weidle UH,König B

更新日期：1998-03-01 00:00:00

abstract：:Cholesterol can promote inflammation by its ability to stimulate the production of reactive oxygen species that result in the formation of pro-inflammatory oxidised phospholipids. High-density lipoproteins (HDLs) are part of the innate immune response and can be either pro- or anti-inflammatory independently of plasma...

journal_title：Expert opinion on investigational drugs

authors： Reddy ST,Anantharamaiah GM,Navab M,Hama S,Hough G,Grijalva V,Garber DW,Datta G,Fogelman AM

更新日期：2006-01-01 00:00:00

abstract：INTRODUCTION:The small tyrosine kinase inhibitor Imatinib Mesylate (Gleevec) protects against diabetes, but it is not known how. AREAS COVERED:It has been suggested that islet amyloid and fibrotic deposits promote beta-cell failure and death, leading to Type-2 diabetes. As Imatinib is known to possess anti-fibrotic/am...

journal_title：Expert opinion on investigational drugs

authors： Welsh N

更新日期：2012-11-01 00:00:00